Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

First-in-Human, Open-Label, Safety, Tolerability, Dose-Finding, Pharmacodynamic and Cardiac Transgene Expression Study of TN-201, a Recombinant Adeno-associated Virus Serotype 9 (AAV9) Containing Myosin Binding Protein C Transgene, in Adults With MYBPC3 Mutation-associated Hypertrophic Cardiomyopathy (HCM)

Next Previous
Trial Profile

First-in-Human, Open-Label, Safety, Tolerability, Dose-Finding, Pharmacodynamic and Cardiac Transgene Expression Study of TN-201, a Recombinant Adeno-associated Virus Serotype 9 (AAV9) Containing Myosin Binding Protein C Transgene, in Adults With MYBPC3 Mutation-associated Hypertrophic Cardiomyopathy (HCM)

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 17 Jul 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs TN-201 (Primary)
  • Indications Hypertrophic cardiomyopathy
  • Focus Adverse reactions; First in man
  • Acronyms MyPeak-1
  • Sponsors Tenaya Therapeutics

Most Recent Events

  • 31 Mar 2025 According to a Tenaya Therapeutics media release, company announced that interim data from the first three patients enrolled in the company MyPEAK-1 Phase 1b/2 clinical trial of TN-201 were highlighted in a Late-Breaker presentation at the 2025 American College of Cardiology Scientific Sessions (ACC.25).
  • 19 Mar 2025 According to a Tenaya Therapeutics media release, data from cohort 1 will be presented at the upcoming American College of Cardiologys Annual Scientific Session
  • 10 Mar 2025 According to a Tenaya Therapeutics media release, Data from Cohort 1 of the MyPEAK-1 clinical trial of TN-201 will be presented on Monday, March 31, 2025, at 9:00 am CT during the Clinical and Investigative Horizons Session.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top